Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 318

1.

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B.

JACC Heart Fail. 2019 Oct 23. pii: S2213-1779(19)30677-8. doi: 10.1016/j.jchf.2019.08.004. [Epub ahead of print]

2.

Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis.

Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, Bekiari E.

Diabetes Obes Metab. 2019 Oct 21. doi: 10.1111/dom.13899. [Epub ahead of print]

PMID:
31637820
3.

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.

Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S; VERIFY study group.

Lancet. 2019 Oct 26;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2. Epub 2019 Sep 18.

PMID:
31542292
4.

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Li Q, Jardine M, Oh R, Heerspink HL, Perkovic V.

J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17.

5.

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B.

Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.

6.

TNFR1 membrane reorganization promotes distinct modes of TNFα signaling.

Morton PE, Perrin C, Levitt J, Matthews DR, Marsh RJ, Pike R, McMillan D, Maloney A, Poland S, Ameer-Beg S, Parsons M.

Sci Signal. 2019 Jul 30;12(592). pii: eaaw2418. doi: 10.1126/scisignal.aaw2418.

PMID:
31363067
7.

A pre-specified statistical analysis plan for the VERIFY study: Vildagliptin efficacy in combination with metformin for early treatment of T2DM.

Matthews DR, Paldánius PM, Stumvoll M, Han J, Bader G, Chiang Y, Proot P, Del Prato S.

Diabetes Obes Metab. 2019 Oct;21(10):2240-2247. doi: 10.1111/dom.13800. Epub 2019 Jun 30.

8.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

9.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

10.

The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm.

Mohan V, Cooper ME, Matthews DR, Khunti K.

Diabetes Ther. 2019 Mar;10(Suppl 1):1-13. doi: 10.1007/s13300-019-0573-y. Epub 2019 Feb 13. Review.

11.

Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans.

Katulanda GW, Katulanda P, Dematapitiya C, Dissanayake HA, Wijeratne S, Sheriff MHR, Matthews DR.

BMC Endocr Disord. 2019 Jan 22;19(1):11. doi: 10.1186/s12902-019-0343-x.

12.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus.

Zhou Z, Lindley RI, Rådholm K, Jenkins B, Watson J, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Shaw W, Oh R, Desai M, Matthews DR, Neal B.

Stroke. 2019 Feb;50(2):396-404. doi: 10.1161/STROKEAHA.118.023009.

13.

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.

Matthews DR, Paldánius PM, Proot P, Foley JE, Stumvoll M, Del Prato S.

Diabet Med. 2019 Apr;36(4):505-513. doi: 10.1111/dme.13886. Epub 2019 Feb 12.

14.

Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist".

Matthews DR, Perkovic V, Mahaffey KW.

Circulation. 2018 Aug 7;138(6):660-661. doi: 10.1161/CIRCULATIONAHA.118.035717. No abstract available.

PMID:
30354619
15.

Kindlin-1 Regulates Epidermal Growth Factor Receptor Signaling.

Michael M, Begum R, Chan GK, Whitewood AJ, Matthews DR, Goult BT, McGrath JA, Parsons M.

J Invest Dermatol. 2019 Feb;139(2):369-379. doi: 10.1016/j.jid.2018.08.020. Epub 2018 Sep 21.

16.

Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review.

Bain SC, Klufas MA, Ho A, Matthews DR.

Diabetes Obes Metab. 2019 Mar;21(3):454-466. doi: 10.1111/dom.13538. Epub 2018 Oct 15. Review.

17.

Glucagon-like peptide-1 receptor agonists and microvascular outcomes in type 2 diabetes: A systematic review and meta-analysis.

Avgerinos I, Karagiannis T, Malandris K, Liakos A, Mainou M, Bekiari E, Matthews DR, Tsapas A.

Diabetes Obes Metab. 2019 Jan;21(1):188-193. doi: 10.1111/dom.13484. Epub 2018 Sep 3.

PMID:
30058208
18.

Among young Sri Lankan patients with diabetes, how do lipid profiles differ between those with and without metabolic syndrome?

Katulanda GW, Dissanayake HA, Katulanda P, Matthews DR, Shine B.

Diabetes Metab Syndr. 2019 Sep - Oct;13(5):3057-3063. doi: 10.1016/j.dsx.2018.07.002. Epub 2018 Jul 17.

PMID:
30037759
19.

Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

Madenidou AV, Paschos P, Karagiannis T, Katsoula A, Athanasiadou E, Kitsios K, Bekiari E, Matthews DR, Tsapas A.

Ann Intern Med. 2018 Aug 7;169(3):165-174. doi: 10.7326/M18-0443. Epub 2018 Jul 10.

PMID:
29987326
20.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

21.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

22.

Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis.

Andreadis P, Karagiannis T, Malandris K, Avgerinos I, Liakos A, Manolopoulos A, Bekiari E, Matthews DR, Tsapas A.

Diabetes Obes Metab. 2018 Sep;20(9):2255-2263. doi: 10.1111/dom.13361. Epub 2018 Jun 10.

PMID:
29756388
23.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus.

Rådholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D, Fulcher G, Barrett TD, Shaw W, Desai M, Matthews DR, Neal B.

Circulation. 2018 Jul 31;138(5):458-468. doi: 10.1161/CIRCULATIONAHA.118.034222.

24.

Prevalence, patterns, and associations of dyslipidemia among Sri Lankan adults-Sri Lanka Diabetes and Cardiovascular Study in 2005-2006.

Katulanda P, Dissanayake HA, De Silva SDN, Katulanda GW, Liyanage IK, Constantine GR, Sheriff R, Matthews DR.

J Clin Lipidol. 2018 Mar - Apr;12(2):447-454. doi: 10.1016/j.jacl.2018.01.006. Epub 2018 Jan 31.

PMID:
29429894
25.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Matthews DR.

N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572. No abstract available.

26.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).

Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group.

Circulation. 2018 Jan 23;137(4):323-334. doi: 10.1161/CIRCULATIONAHA.117.032038. Epub 2017 Nov 13.

27.

Junior hospital doctors-time to rethink the terminology.

Matthews DR.

Lancet. 2017 Nov 4;390(10107):2033-2034. doi: 10.1016/S0140-6736(17)32707-1. Epub 2017 Oct 19. No abstract available.

PMID:
29056413
28.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR; CANVAS Program Collaborative Group.

N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.

29.

Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis.

Stoimenis D, Karagiannis T, Katsoula A, Athanasiadou E, Kazakos K, Bekiari E, Matthews DR, Tsapas A.

Expert Opin Pharmacother. 2017 Jun;18(9):843-851. doi: 10.1080/14656566.2017.1324848. Epub 2017 May 9. Review.

PMID:
28448177
30.

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.

Neal B, Perkovic V, Mahaffey KW, Fulcher G, Erondu N, Desai M, Shaw W, Law G, Walton MK, Rosenthal N, de Zeeuw D, Matthews DR; CANVAS Program collaborative group.

Diabetes Obes Metab. 2017 Jul;19(7):926-935. doi: 10.1111/dom.12924. Epub 2017 Apr 3.

31.

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial.

Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, Erondu N, Desai M, Shaw W, Vercruysse F, Yee J, Deng H, de Zeeuw D; CANVAS-R Trial Collaborative Group.

Diabetes Obes Metab. 2017 Mar;19(3):387-393. doi: 10.1111/dom.12829. Epub 2017 Jan 25.

32.

Presentations of major peripheral arterial disease and risk of major outcomes in patients with type 2 diabetes: results from the ADVANCE-ON study.

Mohammedi K, Woodward M, Hirakawa Y, Zoungas S, Colagiuri S, Hamet P, Harrap S, Poulter N, Matthews DR, Marre M, Chalmers J; ADVANCE Collaborative Group.

Cardiovasc Diabetol. 2016 Sep 2;15(1):129. doi: 10.1186/s12933-016-0446-x.

33.

Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK).

Katulanda P, Hill NR, Stratton I, Sheriff R, De Silva SD, Matthews DR.

BMC Endocr Disord. 2016 Jul 25;16(1):42. doi: 10.1186/s12902-016-0124-8.

34.

Community Interventions for Health can support clinicians in advising patients to reduce tobacco use, improve dietary intake and increase physical activity.

Anthony D, Dyson PA, Lv J, Thankappan KR, Champgane B, Matthews DR.

J Clin Nurs. 2016 Nov;25(21-22):3167-3175. doi: 10.1111/jocn.13323. Epub 2016 Jul 25.

35.

Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59.

Herman WH, Kalyani RR, Wexler DJ, Matthews DR, Inzucchi SE.

Diabetes Care. 2016 Jun;39(6):e88-9. doi: 10.2337/dci16-0003. No abstract available.

36.

Coronin 1B Reorganizes the Architecture of F-Actin Networks for Contractility at Steady-State and Apoptotic Adherens Junctions.

Michael M, Meiring JCM, Acharya BR, Matthews DR, Verma S, Han SP, Hill MM, Parton RG, Gomez GA, Yap AS.

Dev Cell. 2016 Apr 4;37(1):58-71. doi: 10.1016/j.devcel.2016.03.008.

37.

Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles.

Harper CB, Papadopulos A, Martin S, Matthews DR, Morgan GP, Nguyen TH, Wang T, Nair D, Choquet D, Meunier FA.

Sci Rep. 2016 Jan 25;6:19654. doi: 10.1038/srep19654.

38.

Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.

Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, Poulter N, Grobbee R, Cooper M, Jardine M, Chalmers J; ADVANCE Collaborative Group.

Diabetes Obes Metab. 2016 Mar;18(3):289-94. doi: 10.1111/dom.12614. Epub 2016 Jan 15.

PMID:
26661693
39.

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.

Matthews DR, Zinman B, Tong C, Meininger G, Polidori D.

Diabet Med. 2016 Dec;33(12):1744-1747. doi: 10.1111/dme.13033. No abstract available.

PMID:
26600115
40.

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Mathieu C, Woo V, Wysham C, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B; CANVAS trial collaborative group.

Diabetes Obes Metab. 2016 Jan;18(1):82-91. doi: 10.1111/dom.12589. Epub 2015 Dec 8.

PMID:
26450639
41.

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

Karagiannis T, Liakos A, Bekiari E, Athanasiadou E, Paschos P, Vasilakou D, Mainou M, Rika M, Boura P, Matthews DR, Tsapas A.

Diabetes Obes Metab. 2015 Nov;17(11):1065-74. doi: 10.1111/dom.12541. Epub 2015 Sep 23. Review.

PMID:
26395850
42.

Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149.

Inzucchi SE, Matthews DR; Management of Hyperglycemia in Type 2 Diabetes American Diabetes Association and European Association for the Study of Diabetes Position Statement Writing Group.

Diabetes Care. 2015 Aug;38(8):e128-9. doi: 10.2337/dc15-0812. No abstract available.

PMID:
26207068
43.

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial.

Fulcher G, Matthews DR, Perkovic V, de Zeeuw D, Mahaffey KW, Weiss R, Rosenstock J, Capuano G, Desai M, Shaw W, Vercruysse F, Meininger G, Neal B.

Diabetes Ther. 2015 Sep;6(3):289-302. doi: 10.1007/s13300-015-0117-z. Epub 2015 Jun 17.

44.

Successful up-scaled population interventions to reduce risk factors for non-communicable disease in adults: results from the International Community Interventions for Health (CIH) Project in China, India and Mexico.

Dyson PA, Anthony D, Fenton B, Stevens DE, Champagne B, Li LM, Lv J, Ramírez Hernández J, Thankappan KR, Matthews DR; Community Interventions for Health (CIH) collaboration.

PLoS One. 2015 Apr 13;10(4):e0120941. doi: 10.1371/journal.pone.0120941. eCollection 2015.

45.

Reducing Health Risk Factors in Workplaces of Low and Middle-Income Countries.

Anthony D, Dyson PA, Lv J, Thankappan KR, Fernández MT, Matthews DR.

Public Health Nurs. 2015 Sep-Oct;32(5):478-87. doi: 10.1111/phn.12189. Epub 2015 Mar 19.

46.

Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM.

Coban O, Zanetti-Dominguez LC, Matthews DR, Rolfe DJ, Weitsman G, Barber PR, Barbeau J, Devauges V, Kampmeier F, Winn M, Vojnovic B, Parker PJ, Lidke KA, Lidke DS, Ameer-Beg SM, Martin-Fernandez ML, Ng T.

Biophys J. 2015 Mar 10;108(5):1013-26. doi: 10.1016/j.bpj.2015.01.005.

47.

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR.

Diabetologia. 2015 Mar;58(3):429-42. doi: 10.1007/s00125-014-3460-0. Epub 2015 Jan 13. No abstract available.

PMID:
25583541
48.

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR.

Diabetes Care. 2015 Jan;38(1):140-9. doi: 10.2337/dc14-2441. No abstract available.

PMID:
25538310
49.

Time-domain microfluidic fluorescence lifetime flow cytometry for high-throughput Förster resonance energy transfer screening.

Nedbal J, Visitkul V, Ortiz-Zapater E, Weitsman G, Chana P, Matthews DR, Ng T, Ameer-Beg SM.

Cytometry A. 2015 Feb;87(2):104-18. doi: 10.1002/cyto.a.22616. Epub 2014 Dec 18.

50.

Steady-state acceptor fluorescence anisotropy imaging under evanescent excitation for visualisation of FRET at the plasma membrane.

Devauges V, Matthews DR, Aluko J, Nedbal J, Levitt JA, Poland SP, Coban O, Weitsman G, Monypenny J, Ng T, Ameer-Beg SM.

PLoS One. 2014 Oct 31;9(10):e110695. doi: 10.1371/journal.pone.0110695. eCollection 2014.

Supplemental Content

Loading ...
Support Center